Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma
| Image |  |
|---|---|
| Description | scientific article published on 14 November 2020 |
| Author/s |
author: Taku Fujimura |
| Publication date | November 14, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |